Figure. Enrollment, Randomization, and Populations for Analysis in the FOXTROT Trial of Osocimab to Prevent Venous Thromboembolism (VTE).

^aA patient assigned to receive osocimab 1.2 mg/kg postoperatively received 0.3 mg/kg.

^bOf these patients, 62 and 43 were randomized as part of the postoperative and preoperative osocimab phases.

^cRescheduled or canceled knee arthroplasty.

^dReceived commercial enoxaparin instead of study drug.

^eDeviations from inclusion or exclusion criteria, use of prohibited concomitant medications impacting on the primary outcome, and significant changes to study drug intake were considered major protocol deviations.